Sheldon Inwentash

Sheldon Inwentash discloses dealings in Nirvana Life Sciences Inc. (formerly Endocan Solutions Inc.) to SEDI. In total, 5 filings cover trades dated from 17 March 2022 to 9 June 2022.

Every open-market trade on record is a purchase: 3 purchases worth €144k, and no sale. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay.

A typical purchase (the median) is worth €22k. Across 3 purchases, this insider has always bought alone, with no colleague buying within 30 days.

The latest filing, published on 11 June 2022, reports an open-market purchase of €11k in Nirvana Life Sciences Inc. (formerly Endocan Solutions Inc.). Filings reach the SEDI feed a median of 2 days after the trade. This delay matters because a trade only becomes useful information once it is public. Every figure here comes from the filings published by SEDI and describes the past, not future prices; it is not investment advice.